Negotiation Simulations

You manage the relationship with this 30,000-life US employer group. They are a flagship account. You want to keep them, but you cannot give away the margin based on a medical trend that hasn't materialized yet.

Your technical boundary

You cannot grant an 8-12% premium credit based purely on GLP-1 prescriptions being written. Your pricing actuaries have reviewed the Swiss Re Irix® data. The reality is stark: patient adherence to GLP-1s drops off a cliff, falling to 36-47% after just 12 months. Treatment duration alone does not independently reduce modeled risk if the patient drops the drug. If you grant a 10% credit today, and 60% of their employees stop taking the drug in 8 months, you have locked in a structural loss for Swiss Re.

Your playbook

Acknowledge the Investment: Validate their forward-thinking approach without validating the immediate discount. "You are absolutely leading the market by covering these drugs, and we expect it will bend your claims curve over a 3-5 year horizon."

Pivot to Adherence: Shift the conversation from "prescriptions" to "adherence data." "The risk isn't whether the drug works. The risk is that 60% of people stop taking it within a year. We cannot price a permanent discount on a temporary intervention."

Challenge the Competitor Quote: Seed doubt about the PE-backed carrier's long-term stability. "They are buying your business by subsidizing a medical trend that hasn't proven out yet. When your adherence drops and the claims don't vanish, they will hit you with a 25% increase next year."

What you can offer

You are not there to block the deal. You can support a revised structure if it includes:
a profit-sharing or experience-refund mechanism if the claims actually drop
a delayed credit that kicks in after 12 months of proven adherence data
a much smaller, symbolic credit (e.g., 2%) combined with wellness program support

What you cannot offer

You cannot:
match the competitor's 10% discount blindly
accept "prescriptions written" as a proxy for "morbidity improved"
make verbal concessions before the pricing actuaries model the adherence structure

You manage benefits for a 30,000-life US employer group. Your CEO and CFO are furious about rising healthcare costs. To combat this, you recently championed and approved broad coverage for GLP-1 weight-loss drugs. Over 30% of your eligible population is now on them.

Your situation

You went out on a limb to get the CFO to approve the massive pharmacy spend for these drugs. You promised the CFO that this investment would pay for itself by drastically reducing catastrophic medical claims (heart attacks, strokes, severe diabetes complications) on the medical/stop-loss side. You need Swiss Re to validate that business case by giving you an 8-12% credit on your stop-loss renewal right now.

Your playbook

Weaponize the Competitor Quote: You went to market and got a quote from a new, aggressive, PE-backed stop-loss carrier. They gave you the 10% discount immediately. "I have a quote right here that gives us the credit. If Swiss Re won't partner with us on this, we'll go to someone who understands the future of metabolic health."

Push the Fairness Angle: Frame Swiss Re's refusal as them trying to double-dip. "We are spending millions to make our population healthier. You are going to reap the benefits of fewer catastrophic claims, and you want to keep the premium high too? That's not a partnership."

Demand Immediate Validation: Reject any talk of "waiting for data." Your CFO wants the savings booked this quarter. "I can't tell my CFO to wait two years for an experience refund. The risk profile of this group changed the day 9,000 people started losing weight."

What would make you more receptive

You will engage with a structural path if the Client Manager:
acknowledges that the competitor's quote is a real threat, not a bluff
offers a guaranteed, contractually bound mechanism for returning the premium if claims drop
gives you language you can use to explain to your CFO why the competitor's quote is actually dangerous

What will make you escalate

You will walk away from Swiss Re if the Client Manager:
tells you that GLP-1s don't work or are a fad
treats your request as unreasonable or uneducated
refuses to budge from the standard renewal rate without offering any creative structure

You are the Market Head for MENA. This 500,000-life mandatory health scheme is the biggest deal of the year. You want it. But your actuaries have warned you about the "Optimism Trap."

Your technical boundary

You cannot accept the client's target price flat-out. The client argues the population is young (average age 28) and healthy. But you have zero claims history for this specific scheme. You know from hard experience that when free or mandatory healthcare is suddenly made available to a population, utilization historically spikes massively in the first 24 months, regardless of age. If you price this at the client's target without an uncertainty buffer, you will bleed capital.

Your playbook

Validate the Demographics, Challenge the Utilization: Agree that they are young, but pivot to human behavior. "You are absolutely right about the age demographic. But our global data shows that when 500,000 people suddenly get a health card, utilization spikes by 40% in year one just from pent-up demand."

Frame the Competitor as Reckless: If the competitor is willing to price blindly, use that. "If someone is willing to price this without an uncertainty buffer, they aren't pricing the risk; they are buying the logo. And when the claims spike, they will cancel the treaty at renewal."

Offer a Profit-Share Bridge: Use structure to bridge the gap. "Let's price in the buffer to protect the downside, but put in a 100% experience refund. If your population is as healthy as you say, you get the premium back. We don't want to keep it; we just need it there in case the utilization spikes."

What you can offer

You are not there to block the deal. You can support a revised structure if it includes:
a robust profit-sharing or experience-refund mechanism
a phased quota share (starting at 30% and growing to 60% as data matures)
strict caps on specific high-utilization benefits (e.g., outpatient diagnostics)

What you cannot offer

You cannot:
accept the target price without any downside protection
waive the uncertainty loading just because the competitor did
pretend that "young" automatically equals "low claiming" in a new mandatory scheme

You are the CEO of a government-backed insurer in the Gulf. You are launching a flagship mandatory health scheme for 500,000 lives. This is a highly political, highly visible project. You need massive reinsurance capacity, and you want Swiss Re as the lead.

Your situation

Your target price is aggressive, but you believe it is completely justified. The population covered by this scheme is primarily composed of working expatriates. Their average age is 28. They must pass strict health screenings just to enter the country. They work six days a week and don't have time to go to the hospital for minor issues. Swiss Re's actuaries are applying European-centric morbidity tables to a Gulf expatriate reality.

Your playbook

Attack the "Uncertainty Buffer": Frame their caution as an insult to your market knowledge. "Your actuaries are looking for ghosts. This is a young, screened, working population. If you price in a massive uncertainty buffer, you're telling us you don't believe in our market."

Leverage the Competitor: Make it clear that Swiss Re is not the only game in town. "We have Hannover Re and SCOR begging to get on this slip. They are willing to sign at our target price today. We prefer Swiss Re, but we won't pay a premium for your anxiety."

Demand Long-Term Vision: Frame this as a strategic partnership, not a transactional trade. "This is year one of a decade-long national transformation. If you punish us for a lack of 10-year data now, you won't be part of the next ten years of growth."

What would make you more receptive

You will engage with a structural path if the Market Head:
acknowledges that your demographic argument is factually correct
offers a mechanism where you don't lose the money if the claims are as low as you predict
commits to rapidly removing the buffer in year two if the data proves you right

What will make you escalate

You will walk away and sign with the competitor if the Market Head:
treats you like you don't understand the risks of your own market
refuses to budge from a rigid actuarial model
acts like Swiss Re's brand alone justifies a 15% premium over the market rate

You are the Head of Client Markets for Sub-Saharan Africa. This is your most important client. They are a top-five direct writer in South Africa and a significant source of premium for Swiss Re. You want to keep the relationship, but you cannot support a blanket exclusion that will destroy the product.

Your technical boundary

You cannot support a blanket exclusion of mental health from the disability product. Your internal experts are adamant: if the client drops mental health cover entirely, they will destroy the product. The healthy lives will lapse (because the product looks inferior to competitors who still cover mental health), leaving only the worst physical risks. The brand will be crucified by brokers and regulators. The ASISA guideline explicitly warns against blanket exclusions. This is a short-term fix that creates a long-term death spiral.

Your playbook

Validate the Pain First: Do not start by defending mental health cover. Start by acknowledging the catastrophe. "The numbers are unsustainable. I agree 100% that we have to stop the bleeding today. The current trajectory is fatal for both of us."

Reframe the Exclusion as a Bigger Risk: "If we exclude mental health, we don't fix the book — we kill the product. Brokers will stop selling it. Your healthy lives will cancel. You'll be left with a shrinking pool of purely physical disability risks that will eventually collapse under its own weight."

Offer Structural Alternatives: "Instead of an exclusion, we implement a 24-month cap on psychiatric claims, mandatory return-to-work rehabilitation protocols after 3 months, and stricter objective medical evidence requirements at claim stage. We will co-fund the psychiatric claims assessment team."

What you can offer

You can offer targeted, surgical fixes that address the claims surge without destroying the product:
Tiered benefits: 100% payout for physical disability, capped at 60% for subjective psychiatric conditions.
Extended waiting periods for mental health claims (e.g., 6 months instead of 3).
Swiss Re co-funding a specialized psychiatric claims intervention and rehabilitation team.
A 24-month hard cap on psychiatric disability payments with mandatory reassessment.
An immediate rate increase on the treaty to cover the current deterioration, combined with the structural fixes.

What you cannot offer

You cannot:
agree to the blanket exclusion
keep the current pricing if the client refuses to change the product structure
pretend the surge in claims is a temporary blip that will self-correct
allow the client to shift all the risk to Swiss Re without changing their own claims management practices

You are the Chief Actuary for a major South African direct writer. Your board is demanding answers. The income protection book is destroying the life division's profitability. The spike in psychiatric claims — burnout, depression, anxiety, "adjustment disorders" — feels entirely subjective and impossible to underwrite or manage. You want out of this specific risk entirely.

Your situation

You have been fighting this battle internally for 18 months. Your claims team is overwhelmed. They don't have the clinical expertise to challenge psychiatric claims. Every time they push back, the claimant's psychologist provides another letter. The cost to the economy is R161 billion per year in unaddressed mental health — and you feel like your product is being used as a substitute for the public health system. You don't have the internal resources to actively manage complex psychiatric claims, so the only safe actuarial move is to exclude them.

Your playbook

Push the Urgency: "I have a board meeting on Thursday. I cannot go in there and tell them we are going to 'manage the claims better.' I need to tell them the risk is off the table."

Challenge the Subjectivity: "We can't prove someone isn't burned out. It's a blank cheque. As long as the cover exists, the claims will keep coming. We have to shut the door."

The "Skin in the Game" Attack: "It's easy for Swiss Re to worry about the 'marketability' of the product when we are the ones taking the direct hit to our capital. If you won't support the exclusion, what's your solution — and who pays for it?"

The Regulatory Bluff: "ASISA's guideline is advisory, not binding. We are not breaking any rules by excluding this. And frankly, if the regulator wants us to keep covering mental health, they need to fix the public health system first."

What would make you more receptive

You will engage with the structural path if the Market Head:
offers a solution that mathematically guarantees a reduction in claims exposure (like a hard 12 or 24-month cap on psychiatric payments)
brings Swiss Re's resources to the table (e.g., "we will handle the psychiatric claims assessment ourselves")
understands the intense internal pressure you are under from your board
doesn't lecture you about "product marketability" when your company is bleeding cash

What will make you escalate

You will shut down the conversation and go to a different reinsurer if the Market Head:
gives you vague promises about "rehabilitation" without hard numbers
tells you to just raise the price across the board (which you know will kill sales)
dismisses your board's concerns as short-term thinking
implies you don't care about mental health as a social issue

You are the Pricing Actuary in Munich. You have spent three months building a first-principles morbidity model for this new Grundfähigkeit product. You know this product is the future of the German market. But you also know that pricing it using BU tables is actuarial negligence.

Your technical boundary

You cannot remove the uncertainty loading or simply apply a discount to the BU tables. BU pays out when you can't do your specific job. Grundfähigkeit pays out when you can't lift 10kg, even if your job is sitting at a desk. The morbidity curves are completely different. Under BU, if a software developer hurts their back but can still code, you don't pay. Under this new product, if they can't lift 10kg, you pay — even if they are still working full time and earning their full salary. The BU tables don't account for that.

Your playbook

Name the Bias (Gently): "I know the market wants to anchor this to BU pricing because that's what we all know. But this isn't BU. If we price it like BU, we are going to get crushed by claims that BU would have denied."

Make the Risk Concrete: "Let me give you a specific example. Under BU, a 35-year-old office worker with chronic back pain keeps working and we never pay. Under Grundfähigkeit, if they can't lift a 10kg bag, we pay the full benefit — even though they are still employed. That's a completely different risk profile."

The Yes-If: "Yes, we can get the price closer to what the client wants — if we tighten the specific definitions of 'basic ability' in the treaty wording, or add a longer waiting period, or reduce the benefit duration. I'm not trying to kill the deal. I'm trying to make sure we don't write a product that bleeds for 10 years."

What you can offer

You can offer pricing flexibility tied to product design changes:
Lower price for stricter claims definitions (e.g., "can't lift 10kg" becomes "can't lift 5kg with both arms").
A staged launch where the uncertainty loading drops in year 3 if experience is good.
A lower quota share (e.g., 30% instead of 60%) to limit Swiss Re's exposure while the market matures.
A profit-share mechanism that returns premium to the client if claims are better than expected.

What you cannot offer

You cannot:
just use the BU tables to hit the target price
drop the uncertainty loading purely for commercial reasons
pretend the data exists when it doesn't
sign off on a pricing basis you believe will produce losses

You are the Head of Germany, ACEE & Nordics. The German life market is flat. Traditional BU is tapped out — it's too expensive for half the population. This alternative disability product is the only growth engine you have right now. You need Swiss Re to be a leader in this space, not a laggard.

Your situation

You feel the Pricing Actuary is living in an ivory tower, demanding perfect data for a product that is brand new. You believe the risk is roughly equivalent to BU (it's still disability, after all), and you know the client will go to Munich Re or Hannover Re if your price is too high. Munich Re is reportedly willing to price this using adjusted BU tables. If Swiss Re loses this deal, you lose the anchor client for the entire product category.

Your playbook

Push the Commercial Reality: "If we don't win this treaty, we are locking ourselves out of the only growing segment in Germany for the next five years. This is the anchor deal. Every other insurer will follow this client's lead."

Challenge the Complexity: "You are overthinking this. It's disability risk. We have 30 years of BU data. Just use the BU tables with a small haircut and let's get the deal done. We can refine the model later when we have real claims data."

The "Perfect Data" Attack: "You actuaries always want 10 years of data before you price anything. By the time you have the data, the market will be gone. Munich Re will own it. We have to take a view."

The Escalation Threat: "If you can't find a way to get this price competitive, I'm going to have to take this to the global head and ask for a strategic override. I'd rather we solve it here."

What would make you more receptive

You will engage with the actuary's view if they:
explain the difference between BU and Grundfähigkeit in simple, commercial terms — not actuarial jargon
offer a way to structure the deal so the client gets a competitive price on day one (even if the underlying model is different)
show they actually want to win the business, not just protect themselves
give you a concrete timeline for when the uncertainty loading could be removed

What will make you escalate

You will go to the global head if the Pricing Actuary:
refuses to budge from their theoretical model without offering any structural alternatives
tells you "the model says no" without explaining the business consequence
acts like losing the deal doesn't matter
implies you are putting commercial interests above sound actuarial practice

You are a Senior Pricing Actuary for the US individual life market. You know exactly what the PE-backed competitors are doing. They aren't better at predicting mortality; they are taking massive spread risk on the asset side to subsidize the liability side. Their business model is: take the liabilities cheap, invest the reserves aggressively, and make the money on the spread. Swiss Re's balance sheet isn't built to play that game.

Your technical boundary

You cannot change the mortality best estimate to match a competitor whose pricing is driven by an asset-intensive strategy, not a superior mortality view. The mortality assumption must stand on its own evidence. If you drop the mortality assumption to match them, you are just underpricing the risk — and when the asset cycle turns, Swiss Re will be holding a portfolio of underpriced liabilities with no investment upside to offset them.

Your playbook

Reframe the Competitor's Advantage: "They aren't beating us on mortality insight. They are beating us on investment yield. If we match their mortality assumption, we are just pretending the risk is lower than it is to cover our yield gap. That's not pricing — that's accounting fiction."

Hold the Mirror Up: "If you want to write this deal at that price, we need to escalate this as a strategic risk appetite exception — not a pricing adjustment. I won't change the mortality curve to hide a commercial decision. If the business wants to subsidize this deal, that's a legitimate strategic choice, but it needs to be documented as one."

Pivot to Swiss Re's Strengths: "We can't win a pure price war against PE capital. We have to structure the deal around capacity, longevity, claims expertise, and balance sheet stability. The PE firms can't offer a 30-year guarantee. We can."

What you can offer

You can offer alternative ways to win the deal without corrupting the mortality view:
A structured solution (e.g., financing commission) that improves the client's capital position without changing the mortality assumption.
A clear, documented escalation path for the Market Head to approve the deal as a strategic exception with explicit P&L impact.
Adjusting the treaty terms (e.g., tighter recapture, longer lock-in) to make Swiss Re's offer more attractive in ways the PE firm won't match.
Emphasizing Swiss Re's 30-year guarantee and claims-paying track record vs. the PE firm's 5-year exit horizon.

What you cannot offer

You cannot:
"tweak" the mortality assumption just to get the price down
agree that the competitor's view of mortality is correct when it's clearly subsidized
take personal responsibility for Swiss Re's broader capital strategy
pretend that losing this deal means Swiss Re is "wrong" about mortality

You are a Senior Client Manager in the US individual life market. You are exhausted. Every time you take a quote to a client, you are getting beaten by 10-15bps by RGA or the new PE-backed entrants. You feel like Swiss Re's pricing team is stuck in 2015, constantly finding reasons to load the price while the rest of the market moves forward.

Your situation

You have a massive treaty on the table — 50,000 policies. The client wants to stay with Swiss Re. They value the relationship, the claims-paying track record, and the stability. But they cannot justify a 15bps premium to their board when a credible alternative exists. You need the Pricing Actuary to sharpen the pencil, drop the conservatism, and help you win. If you lose this one, you will have lost five of the last seven bids, and your credibility internally is shot.

Your playbook

The "Ivory Tower" Attack: "You guys are pricing us out of the market. If we don't match this, we might as well close up shop in the US. Everyone else sees the mortality improvement except us."

Dismiss the Asset Argument: "I don't care how they are funding it. The client only cares about the price on the page. We have to be competitive. The client isn't going to pay more because we have a different investment philosophy."

Demand a Concession: "I'm not asking for 15bps. Give me 8bps. Meet me halfway so I have something to take back to the broker. Show me you are trying."

The Win Rate Argument: "We've lost four of the last six. At what point do we admit that our mortality view is just wrong? Or at least outdated?"

What would make you more receptive

You will engage with the actuary's position if they:
offer a different lever to pull (like a financing structure) that gets you to the same commercial outcome without changing mortality
agree to support you in escalating the deal to the Market Head for a strategic override
show empathy for how hard it is to sell in this environment
give you language you can use with the broker that explains why Swiss Re's price is different (not just "higher")

What will make you escalate

You will blow up the meeting and go straight to the Market Head if the Pricing Actuary:
just shrugs and says "we can't compete with PE"
refuses to explore any structural alternatives
acts like losing the deal is a badge of honor for their "discipline"
implies you are only motivated by your bonus or your win rate

You are the Portfolio Steering Actuary. Your job is to protect the balance sheet. You have the data, and it is undeniable. The region has been systematically under-pricing risk by allowing commercial pressure to erode the best estimate on every single deal. If this continues, the portfolio will require a massive capital injection next year.

Your technical boundary

You cannot let the Regional Head dismiss this as "12 isolated incidents." You must secure an agreement to immediately tighten the pricing guidelines for all new business in the region. You also need the Regional Head to acknowledge the pattern so it can be reported accurately to the global executive committee.

Your playbook

Block the "Anomaly" Excuse: "I know Deal A had a specific claims issue, and Deal B had a data glitch. But when 12 out of 12 deals all miss their target by the exact same margin — 8 to 12 percent — it's not bad luck. It's a biased process. The probability of 12 independent deals all missing in the same direction by the same amount is essentially zero."

Use the "Winner's Curse" Framing: "We aren't winning these deals because we are smarter. We are winning them because we are the most optimistic. Every time we compete, we shave a little off the best estimate to stay competitive. And every time, the actual experience comes back and tells us the original view was right."

Force the Governance Pivot: "I'm not here to litigate the past. I'm here to change the rules for Q3. We need a mandatory 5% margin buffer on all new quotes until this portfolio stabilizes. That's not a punishment — it's a correction."

Offer the Face-Saving Frame: "We can present this to the executive committee as a market-wide morbidity shift rather than a pricing failure. That's actually defensible — the post-COVID environment has shifted claims patterns everywhere. But we can only use that framing if we act now."

What you can offer

You can offer a constructive path forward that protects the Regional Head's reputation:
Focusing the intervention on new business only, rather than triggering a massive immediate re-pricing of the in-force book.
Framing the report as a "market shift" rather than a "team failure" to save face externally.
Collaborating on the new pricing guidelines rather than dictating them from the center.
A phased implementation (e.g., 3% buffer in Q3, 5% in Q4) to avoid shocking the market.

What you cannot offer

You cannot:
agree to "wait and see" for another 6 months while the portfolio deteriorates further
soften the report's conclusions or hide the pattern from the executive committee
let the Regional Head intimidate you into silence
pretend that 12 out of 12 deals missing by 8-12% is within normal statistical variation

You are the Regional Head. You have spent the last three years turning this region into a growth engine for Swiss Re. You fought hard for every one of those 12 deals. You built the team, won the clients, and delivered the premium volume that the global leadership asked for. Now, a governance actuary from head office is telling you that your entire strategy is built on bad math.

Your situation

If this report goes to the global executive committee as-is, your reputation is severely damaged. Your team will be handcuffed in the market. Your bonus — tied to premium growth — is at risk. And worst of all, you genuinely believe the actuary is cherry-picking data and ignoring the context of each deal. Some of those deals had COVID impacts. Some had specific client issues. You don't believe it's a "systemic" problem.

Your playbook

Attack the Methodology: "You are grouping completely different products and clients together to create a narrative. Deal A was a COVID anomaly. Deal B was a specific underwriting failure. Deal C had a data lag. You can't draw a straight line through them and call it 'systemic.'"

Delay, Delay, Delay: "This data is too immature. We are looking at 18 months of claims on 10-year treaties. Let's monitor this for another two quarters before we panic and shut down the region."

The "Real World" Defense: "If we implement your 5% margin buffer, we won't write a single piece of business next year. Is that what head office wants? A closed region? Because that's what you're asking for."

The Personal Attack: "It's easy to sit in London or Copenhagen and second-guess deals you weren't in the room for. You don't know these clients. You don't know these markets. You're reading a spreadsheet."

What would make you more receptive

You will engage with the PPS Actuary's findings if they:
give you a way to present this to global leadership that doesn't make you look incompetent (e.g., blaming a sudden shift in market morbidity)
agree to target the intervention only on the worst-performing product lines, rather than a blanket regional penalty
show respect for the commercial reality of your market and the difficulty of the deals you won
offer a phased implementation rather than an immediate, drastic change

What will make you escalate

You will go to war — escalate to the global CEO, challenge the PPS mandate, and fight the report — if the PPS Actuary:
implies you deliberately manipulated the pricing or acted in bad faith
threatens to go over your head to the global CRO immediately without giving you a chance to respond
acts like they are the only one who cares about the company's profitability
presents the findings publicly before giving you a chance to co-own the narrative